DURECT (DRRX) Stock Price, News & Analysis

Company Overview

DURECT Corporation (NASDAQ: DRRX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel, small-molecule therapeutics in areas of high unmet medical need. Founded in 1998 and headquartered in California, DURECT pursues programs in inflammatory, fibrotic, and central nervous system disorders. The company’s research is supported by a proprietary drug delivery platform designed to optimize the release profiles and bioavailability of its drug candidates.

The company’s leading clinical asset, DUR-928, is an endogenous regulator being evaluated for the treatment of liver diseases, kidney disorders, and acute organ injury. Another key program, POSIMIR, is an investigational, long-acting local analgesic formulation intended to manage postsurgical pain. DURECT also maintains a robust preclinical pipeline that leverages its small-molecule chemistry expertise to target novel pathways in autoimmune conditions and oncology.

Beyond its internal pipeline, DURECT commercializes RELiZORB®, an immobilized lipase cartridge designed to improve fat absorption in patients receiving enteral nutrition, and it has partnered with pharmaceutical companies to license its drug delivery technologies. The IntraPhase™ controlled-release platform is used to develop injectable depot formulations, while its ALZET® osmotic pumps are utilized by researchers worldwide for sustained compound delivery in preclinical studies.

Under the leadership of President and CEO Andrew B. Allen, DURECT collaborates with academic institutions, biotechnology firms, and pharmaceutical partners to advance both its therapeutic candidates and delivery systems. The company’s global reach extends through strategic alliances and licensing agreements aimed at accelerating clinical development and expanding access to its proprietary technologies.

Key Stats

• Today's Range: $1.91 to $1.91
• 50-Day Range: $1.85 to $1.96
• 52-Week Range: $0.48 to $2.64
• Volume: N/A
• Average Volume: 699,433 shs
• Market Capitalization: $59.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

DRRX Stock Analysis - Frequently Asked Questions

How were DURECT's earnings last quarter?

DURECT Corporation (NASDAQ:DRRX) posted its quarterly earnings data on Tuesday, August, 12th. The specialty pharmaceutical company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.06. The specialty pharmaceutical company had revenue of $0.45 million for the quarter, compared to the consensus estimate of $0.32 million. DURECT had a negative trailing twelve-month return on equity of 259.16% and a negative net margin of 96.19%.

When did DURECT's stock split?

DURECT shares reverse split on the morning of Tuesday, December 6th 2022.The 1-10 reverse split was announced on Tuesday, December 6th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of DURECT own?

Based on aggregate information from My MarketBeat watchlists, some other companies that DURECT investors own include CymaBay Therapeutics (CBAY), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), GE Aerospace (GE), Catalyst Pharmaceuticals (CPRX) and Pfizer (PFE).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 10/21/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DRRX
• CIK: 1082038
• Web: www.durect.com
• Phone: (408) 777-1417
• Fax: 408-777-3577
• Employees: 80
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.32 million
• Net Margins: -96.19%
• Pretax Margin: -416.01%
• Return on Equity: -259.16%
• Return on Assets: -71.78%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.98
• Quick Ratio: 0.95

Sales & Book Value

• Annual Sales: $1.66 million
• Price / Sales: 35.80
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.29 per share
• Price / Book: 6.59

Miscellaneous

• Outstanding Shares: 31,054,000
• Free Float: 30,060,000
• Market Cap: $59.31 million
• Optionable: Optionable
• Beta: 0.92